Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia
We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical lipidology 2018-07, Vol.12 (4), p.883-887 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 887 |
|---|---|
| container_issue | 4 |
| container_start_page | 883 |
| container_title | Journal of clinical lipidology |
| container_volume | 12 |
| creator | Béliard, Sophie Di Filippo, Mathilde Kaplanski, Gilles Valéro, René |
| description | We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
•Autoimmune hypertriglyceridemia is a rare but severe metabolic disorder.•Rituximab is a rational and obvious therapy for autoimmune hyperlipidemia.•Rituximab is highly effective and safe for treating autoimmune hyperlipidemia. |
| doi_str_mv | 10.1016/j.jacl.2018.04.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01996207v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933287418302095</els_id><sourcerecordid>2042759201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-8c43fe4c3204b5320a75c70060bfd2b7ca313ba1ed8c78043c3e846e6e47d1353</originalsourceid><addsrcrecordid>eNp9kc1q3TAQhUVpadK0L5BF0LKB2JEs2ZIhmxDS3sKFbpq1kOXxtS7-iyQn8aLvXhmnoatuNMPwzdFwDkLnlKSU0OL6mB616dKMUJkSnhJK36FTKkWRcCHL97EvGUsyKfgJ-uT9kZA8FyT_iE6yUkieC36Kfu_soe0WDE1jjTZ2nP0V7sbhkARw_RUOzh66xYCzNcT5c2yGA362ocXOhvnF9rrCoQWnpwXbAWs86WBhCBuj5zDavp8HwO0ygftXrrf6M_rQ6M7Dl9d6hh6-3f-62yX7n99_3N3uE8MZD4mMpQFuWEZ4lcdXi9wIQgpSNXVWCaMZZZWmUEsjJOHMMJC8gAK4qCnL2Rm63HRb3anJxaPdokZt1e52r9YZoWVZZEQ80ch-3djJjY8z-KB66w10nR4guqPiDZnIy-h6RLMNNW703kHzpk2JWiNSR7VGpNaIFOHxm3Xp4lV_rnqo31b-ZhKBmw2A6MiTBae8iY4aqK0DE1Q92v_p_wHtsqQn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2042759201</pqid></control><display><type>article</type><title>Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Béliard, Sophie ; Di Filippo, Mathilde ; Kaplanski, Gilles ; Valéro, René</creator><creatorcontrib>Béliard, Sophie ; Di Filippo, Mathilde ; Kaplanski, Gilles ; Valéro, René</creatorcontrib><description>We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
•Autoimmune hypertriglyceridemia is a rare but severe metabolic disorder.•Rituximab is a rational and obvious therapy for autoimmune hyperlipidemia.•Rituximab is highly effective and safe for treating autoimmune hyperlipidemia.</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2018.04.011</identifier><identifier>PMID: 29784574</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-LPL autoantibody ; Autoimmune hyperlipidemia ; Endocrinology and metabolism ; Human health and pathology ; Hyperchylomicronemia ; Life Sciences ; Rituximab ; Type 1 hyperlipidemia</subject><ispartof>Journal of clinical lipidology, 2018-07, Vol.12 (4), p.883-887</ispartof><rights>2018 National Lipid Association</rights><rights>Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-8c43fe4c3204b5320a75c70060bfd2b7ca313ba1ed8c78043c3e846e6e47d1353</citedby><cites>FETCH-LOGICAL-c434t-8c43fe4c3204b5320a75c70060bfd2b7ca313ba1ed8c78043c3e846e6e47d1353</cites><orcidid>0000-0001-6206-5908 ; 0000-0002-6000-5028</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1933287418302095$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29784574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-01996207$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Béliard, Sophie</creatorcontrib><creatorcontrib>Di Filippo, Mathilde</creatorcontrib><creatorcontrib>Kaplanski, Gilles</creatorcontrib><creatorcontrib>Valéro, René</creatorcontrib><title>Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
•Autoimmune hypertriglyceridemia is a rare but severe metabolic disorder.•Rituximab is a rational and obvious therapy for autoimmune hyperlipidemia.•Rituximab is highly effective and safe for treating autoimmune hyperlipidemia.</description><subject>Anti-LPL autoantibody</subject><subject>Autoimmune hyperlipidemia</subject><subject>Endocrinology and metabolism</subject><subject>Human health and pathology</subject><subject>Hyperchylomicronemia</subject><subject>Life Sciences</subject><subject>Rituximab</subject><subject>Type 1 hyperlipidemia</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1q3TAQhUVpadK0L5BF0LKB2JEs2ZIhmxDS3sKFbpq1kOXxtS7-iyQn8aLvXhmnoatuNMPwzdFwDkLnlKSU0OL6mB616dKMUJkSnhJK36FTKkWRcCHL97EvGUsyKfgJ-uT9kZA8FyT_iE6yUkieC36Kfu_soe0WDE1jjTZ2nP0V7sbhkARw_RUOzh66xYCzNcT5c2yGA362ocXOhvnF9rrCoQWnpwXbAWs86WBhCBuj5zDavp8HwO0ygftXrrf6M_rQ6M7Dl9d6hh6-3f-62yX7n99_3N3uE8MZD4mMpQFuWEZ4lcdXi9wIQgpSNXVWCaMZZZWmUEsjJOHMMJC8gAK4qCnL2Rm63HRb3anJxaPdokZt1e52r9YZoWVZZEQ80ch-3djJjY8z-KB66w10nR4guqPiDZnIy-h6RLMNNW703kHzpk2JWiNSR7VGpNaIFOHxm3Xp4lV_rnqo31b-ZhKBmw2A6MiTBae8iY4aqK0DE1Q92v_p_wHtsqQn</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Béliard, Sophie</creator><creator>Di Filippo, Mathilde</creator><creator>Kaplanski, Gilles</creator><creator>Valéro, René</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-6206-5908</orcidid><orcidid>https://orcid.org/0000-0002-6000-5028</orcidid></search><sort><creationdate>20180701</creationdate><title>Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia</title><author>Béliard, Sophie ; Di Filippo, Mathilde ; Kaplanski, Gilles ; Valéro, René</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-8c43fe4c3204b5320a75c70060bfd2b7ca313ba1ed8c78043c3e846e6e47d1353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-LPL autoantibody</topic><topic>Autoimmune hyperlipidemia</topic><topic>Endocrinology and metabolism</topic><topic>Human health and pathology</topic><topic>Hyperchylomicronemia</topic><topic>Life Sciences</topic><topic>Rituximab</topic><topic>Type 1 hyperlipidemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Béliard, Sophie</creatorcontrib><creatorcontrib>Di Filippo, Mathilde</creatorcontrib><creatorcontrib>Kaplanski, Gilles</creatorcontrib><creatorcontrib>Valéro, René</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Béliard, Sophie</au><au>Di Filippo, Mathilde</au><au>Kaplanski, Gilles</au><au>Valéro, René</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>12</volume><issue>4</issue><spage>883</spage><epage>887</epage><pages>883-887</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
•Autoimmune hypertriglyceridemia is a rare but severe metabolic disorder.•Rituximab is a rational and obvious therapy for autoimmune hyperlipidemia.•Rituximab is highly effective and safe for treating autoimmune hyperlipidemia.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29784574</pmid><doi>10.1016/j.jacl.2018.04.011</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6206-5908</orcidid><orcidid>https://orcid.org/0000-0002-6000-5028</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-2874 |
| ispartof | Journal of clinical lipidology, 2018-07, Vol.12 (4), p.883-887 |
| issn | 1933-2874 1876-4789 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01996207v1 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Anti-LPL autoantibody Autoimmune hyperlipidemia Endocrinology and metabolism Human health and pathology Hyperchylomicronemia Life Sciences Rituximab Type 1 hyperlipidemia |
| title | Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A21%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20efficacious,%20long-term,%20triglyceride%20lowering%20with%20rituximab%20therapy%20in%20a%20patient%20with%20autoimmune%20hypertriglyceridemia&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=B%C3%A9liard,%20Sophie&rft.date=2018-07-01&rft.volume=12&rft.issue=4&rft.spage=883&rft.epage=887&rft.pages=883-887&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2018.04.011&rft_dat=%3Cproquest_hal_p%3E2042759201%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2042759201&rft_id=info:pmid/29784574&rft_els_id=S1933287418302095&rfr_iscdi=true |